A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies

(2013) K. Sideras et al.   CANCER TREATMENT REVIEWS

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

(2013) Luana Calabrò et al.   LANCET ONCOLOGY

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma

(2012) J. Wolchok   ANNALS OF ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

(2010) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma

(2010) C. Ralph et al.   CLINICAL CANCER RESEARCH

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma

(2009) Luis H. Camacho et al.   JOURNAL OF CLINICAL ONCOLOGY